NEW YORK (GenomeWeb News) – Source BioScience said today that it will provide drugmaker AstraZeneca with a companion diagnostic testing service for lung cancer patients in the UK.
The service agreement with AstraZeneca will enable doctors at the National Health Service to identify which lung cancer patients have certain genetic mutations in their tumors that may make them sensitive to tyrosine kinase inhibitor therapies, which in turn may help guide doctors' treatment decisions.
Source BioScience will conduct full pathology reviews, genetic testing, and diagnostic analysis at its labs in Nottingham and return the reports within five working days.
"If we are able to provide better diagnostics information for clinicians, this will help ensure that treatment pathways are managed more effectively, positively impacting the clinical outcome and cost effectiveness of therapy," Source BioScience Managing Director Nick Ash said in a statement. "Increasing demand for targeted therapies to improve treatment success and reduce costs is generating demand for companion diagnostics to accompany those therapies," Ash added.
The service will be funded by AstraZeneca, but specific financial terms of the agreement were not released.